We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have lost about 17.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Myriad due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -73.61% due to these changes.
VGM Scores
At this time, Myriad has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Myriad has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Halozyme Therapeutics (HALO - Free Report) , a stock from the same industry, has gained 11.8%. The company reported its results for the quarter ended December 2024 more than a month ago.
Halozyme Therapeutics reported revenues of $298.01 million in the last reported quarter, representing a year-over-year change of +29.6%. EPS of $1.26 for the same period compares with $0.82 a year ago.
For the current quarter, Halozyme Therapeutics is expected to post earnings of $0.96 per share, indicating a change of +21.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.1% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Halozyme Therapeutics. Also, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Myriad Genetics (MYGN - Free Report) . Shares have lost about 17.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Myriad due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -73.61% due to these changes.
VGM Scores
At this time, Myriad has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Myriad has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Halozyme Therapeutics (HALO - Free Report) , a stock from the same industry, has gained 11.8%. The company reported its results for the quarter ended December 2024 more than a month ago.
Halozyme Therapeutics reported revenues of $298.01 million in the last reported quarter, representing a year-over-year change of +29.6%. EPS of $1.26 for the same period compares with $0.82 a year ago.
For the current quarter, Halozyme Therapeutics is expected to post earnings of $0.96 per share, indicating a change of +21.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.1% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Halozyme Therapeutics. Also, the stock has a VGM Score of B.